GlassScriptPhysician profile
Thomas P Rak
NPI 1124019807
$1,804.26
in general payments reported to CMS, 2019-2025
15 companies · $29.87 in 2025
The $29.87 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $171 · 2021: $226 · 2022: $804 · 2023: $99.95 · 2024: $311 · 2025: $29.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $714.42 | 2019-2022 | |
| Galderma Laboratories, L.P. | $340.36 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $284.16 | 2023-2024 | Libtayo |
| W. L. Gore & Associates, INC. | $127.01 | 2019 | |
| Tela Bio, INC. | $65.52 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Endo Pharmaceuticals INC. | $51.68 | 2022-2024 | Xiaflex |
| Acelrx Pharmaceuticals, INC. | $45.72 | 2021 | |
| Revance Therapeutics, INC. | $40.79 | 2024 | Daxxify |
| Mentor Worldwide LLC | $34.70 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $29.87 | 2025 | |
| Sanara Medtech INC. | $19.41 | 2024 | Celleraterx |
| Smith+Nephew, INC. | $18.78 | 2021 | |
| Genentech USA, INC. | $12.94 | 2019 | |
| Sientra, INC. | $9.49 | 2019 | |
| Microaire Surgical Instruments LLC | $9.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.